Sunshine Biopharma, Inc. (SBFM)
NASDAQ: SBFM · Real-Time Price · USD
1.440
-0.050 (-3.36%)
At close: Aug 29, 2025, 4:00 PM
1.500
+0.060 (4.17%)
After-hours: Aug 29, 2025, 6:14 PM EDT
Sunshine Biopharma Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Sunshine Biopharma stock has a target of 15, which predicts a 941.67% increase from the current stock price of 1.44.
Price Target: $15 (+941.67%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Dec 5, 2024.
Analyst Ratings
According to 1 stock analyst, the rating for Sunshine Biopharma is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|
| Strong Buy | 1 | 1 | 1 |
| Buy | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 |
| Total | 1 | 1 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Aegis Capital | Aegis Capital | Strong Buy Reiterates $15 | Strong Buy | Reiterates | $15 | +941.67% | Dec 5, 2024 |
| Aegis Capital | Aegis Capital | Strong Buy Initiates $5,200 | Strong Buy | Initiates | $5,200 | +361,011.11% | Aug 7, 2023 |
Financial Forecast
Revenue This Year
46.11M
from 34.87M
Increased by 32.20%
Revenue Next Year
61.20M
from 46.11M
Increased by 32.74%
EPS This Year
-0.58
from -7.32
EPS Next Year
0.08
from -0.58
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 |
|---|---|---|
| High | 47.5M | 63.0M |
| Avg | 46.1M | 61.2M |
| Low | 44.3M | 58.8M |
Revenue Growth
| Revenue Growth | 2025 | 2026 |
|---|---|---|
| High | 36.1% | 36.6% |
| Avg | 32.2% | 32.7% |
| Low | 27.0% | 27.5% |
EPS Forecast
| EPS | 2025 | 2026 |
|---|---|---|
| High | -0.60 | 0.08 |
| Avg | -0.58 | 0.08 |
| Low | -0.56 | 0.08 |
EPS Growth
| EPS Growth | 2025 | 2026 |
|---|---|---|
| High | - | - |
| Avg | - | - |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.